Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (471-480 of 483) with videos related to

Pageof 49
Sort By:
The Lancet. Haematology|May 15, 2023
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trialHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
British Journal of Haematology|November 9, 2019
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC studyCatherine Thieblemont, Susannah Howlett, René-Olivier Casasnovas, et al.
Hepatology Communications|November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohortTiago de Castro, Sabrina Welland, Leonie Jochheim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser, Gilles Salles, Laurie H Sehn, et al.
The New England Journal of Medicine|December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R Bishop, Michael Dickinson, Duncan Purtill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
The Lancet. Haematology|January 29, 2021
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort studyLisa Pleyer, Michael Leisch, Alexandra Kourakli, et al.
Cancer Cell|January 13, 2026
Single-cell integration and multi-modal profiling reveals phenotypes and spatial organization of neutrophils in colorectal cancerValentin Marteau, Niloofar Nemati, Kristina Handler, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Pageof 49

Showing results (471-480 of 483) with videos related to

Sort By:
Pageof 49
The Lancet. Haematology|May 15, 2023
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trialHartmut Döhner, Daniela Weber, Julia Krzykalla, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
British Journal of Haematology|November 9, 2019
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC studyCatherine Thieblemont, Susannah Howlett, René-Olivier Casasnovas, et al.
Hepatology Communications|November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohortTiago de Castro, Sabrina Welland, Leonie Jochheim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2025
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell LymphomaFranck Morschhauser, Gilles Salles, Laurie H Sehn, et al.
The New England Journal of Medicine|December 14, 2021
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell LymphomaMichael R Bishop, Michael Dickinson, Duncan Purtill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
The Lancet. Haematology|January 29, 2021
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort studyLisa Pleyer, Michael Leisch, Alexandra Kourakli, et al.
Cancer Cell|January 13, 2026
Single-cell integration and multi-modal profiling reveals phenotypes and spatial organization of neutrophils in colorectal cancerValentin Marteau, Niloofar Nemati, Kristina Handler, et al.
Lancet (London, England)|July 6, 2024
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trialPeter Borchmann, Justin Ferdinandus, Gundolf Schneider, et al.
Pageof 49